KR102284389B1 - Cd206 발현 세포-관련 장애를 진단 및 치료하기 위한 조성물, 방법 및 키트 - Google Patents

Cd206 발현 세포-관련 장애를 진단 및 치료하기 위한 조성물, 방법 및 키트 Download PDF

Info

Publication number
KR102284389B1
KR102284389B1 KR1020167004069A KR20167004069A KR102284389B1 KR 102284389 B1 KR102284389 B1 KR 102284389B1 KR 1020167004069 A KR1020167004069 A KR 1020167004069A KR 20167004069 A KR20167004069 A KR 20167004069A KR 102284389 B1 KR102284389 B1 KR 102284389B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
carrier molecule
tilmanocept
dextran backbone
expressing cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020167004069A
Other languages
English (en)
Korean (ko)
Other versions
KR20160055791A (ko
Inventor
프레드릭 코프
마이클 블루
웬디 메츠
래리 슐레진저
Original Assignee
나비디아 바이오파마슈티컬즈, 인크.
오하이오 스테이트 이노베이션 파운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 나비디아 바이오파마슈티컬즈, 인크., 오하이오 스테이트 이노베이션 파운데이션 filed Critical 나비디아 바이오파마슈티컬즈, 인크.
Priority to KR1020217023825A priority Critical patent/KR20210095972A/ko
Publication of KR20160055791A publication Critical patent/KR20160055791A/ko
Application granted granted Critical
Publication of KR102284389B1 publication Critical patent/KR102284389B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
KR1020167004069A 2013-07-22 2014-07-22 Cd206 발현 세포-관련 장애를 진단 및 치료하기 위한 조성물, 방법 및 키트 Expired - Fee Related KR102284389B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217023825A KR20210095972A (ko) 2013-07-22 2014-07-22 Cd206 발현 세포-관련 장애를 진단 및 치료하기 위한 조성물, 방법 및 키트

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361857232P 2013-07-22 2013-07-22
US61/857,232 2013-07-22
US201361879649P 2013-09-18 2013-09-18
US61/879,649 2013-09-18
PCT/US2014/047708 WO2015013341A1 (en) 2013-07-22 2014-07-22 Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217023825A Division KR20210095972A (ko) 2013-07-22 2014-07-22 Cd206 발현 세포-관련 장애를 진단 및 치료하기 위한 조성물, 방법 및 키트

Publications (2)

Publication Number Publication Date
KR20160055791A KR20160055791A (ko) 2016-05-18
KR102284389B1 true KR102284389B1 (ko) 2021-08-03

Family

ID=51352773

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020167004069A Expired - Fee Related KR102284389B1 (ko) 2013-07-22 2014-07-22 Cd206 발현 세포-관련 장애를 진단 및 치료하기 위한 조성물, 방법 및 키트
KR1020217023825A Ceased KR20210095972A (ko) 2013-07-22 2014-07-22 Cd206 발현 세포-관련 장애를 진단 및 치료하기 위한 조성물, 방법 및 키트

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217023825A Ceased KR20210095972A (ko) 2013-07-22 2014-07-22 Cd206 발현 세포-관련 장애를 진단 및 치료하기 위한 조성물, 방법 및 키트

Country Status (11)

Country Link
US (2) US20150023876A1 (https=)
EP (1) EP3024493A1 (https=)
JP (1) JP6607854B2 (https=)
KR (2) KR102284389B1 (https=)
CN (2) CN105764529A (https=)
AU (3) AU2014293198A1 (https=)
CA (1) CA2918782C (https=)
HK (1) HK1225623A1 (https=)
IL (1) IL243645B (https=)
WO (1) WO2015013341A1 (https=)
ZA (1) ZA201600453B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196272A1 (en) 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
US10806803B2 (en) 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
WO2016011415A2 (en) * 2014-07-17 2016-01-21 Ohio State Innovation Foundation Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
EP3352797A1 (en) * 2015-09-25 2018-08-01 Serene, Llc Sn-117m labeled mannose coupled dextran amine
EP3522938A4 (en) * 2016-10-04 2020-06-24 Cardinal Health 414, LLC COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING MACROPHAGE-RELATED DISORDERS USING A CARBOHYDRATE MACROMOLECULAR SUPPORT
CN110139655A (zh) * 2016-10-07 2019-08-16 纳维迪亚生物制药有限公司 诊断和治疗病毒性感染的化合物和方法
MX2019004033A (es) * 2016-10-07 2019-12-05 Navidea Biopharmaceuticals Inc Compuestos y composiciones para el tratamiento de la leishmaniasis y metodos de diagnostico y tratamiento que utilizan los mismos.
US11286172B2 (en) 2017-02-24 2022-03-29 BWXT Isotope Technology Group, Inc. Metal-molybdate and method for making the same
US11363709B2 (en) 2017-02-24 2022-06-14 BWXT Isotope Technology Group, Inc. Irradiation targets for the production of radioisotopes
US20190021608A1 (en) * 2017-05-19 2019-01-24 Navidea Biopharmaceuticals, Inc. CD206+ Macrophage-Specific Molecular Imaging Probe Compositions and Methods and the Noninvasive Quantification of Arterial Wall Macrophage Infiltration in Humans
CA3070494A1 (en) * 2017-07-21 2019-01-24 Navidea Biopharmaceuticals, Inc. Use of 99mtc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventions
CN114025666A (zh) * 2019-01-25 2022-02-08 纳维迪亚生物制药有限公司 用于评估巨噬细胞介导的病理学的组合物和方法
GB201902810D0 (en) * 2019-03-01 2019-04-17 Vidya Holdings Ltd Disposition of reagents in assay device
WO2020198622A1 (en) * 2019-03-27 2020-10-01 Navidea Biopharmaceuticals, Inc. Compositions and methods for altering macrophage phenotype
WO2021034953A1 (en) * 2019-08-19 2021-02-25 Navidea Biopharmaceuticals, Inc. Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells
WO2021067479A1 (en) * 2019-09-30 2021-04-08 Navidea Biopharmaceuticals, Inc. Compositions and related methods for blocking off-target localization of mannosylated dextrans and other cd206 ligands
GB201915222D0 (en) * 2019-10-21 2019-12-04 Univ Court Univ Of Glasgow Diagnostic and prognostic biomarkers of disease remission in rheumatoid arthritis
CA3168879A1 (en) * 2020-07-08 2022-01-13 Navidea Biopharmaceuticals, Inc. Synthesis of uniformly defined molecular weight mannosylated dextrans and derivatives thereof
WO2022157373A1 (en) * 2021-01-25 2022-07-28 Vrije Universiteit Brussel Compositions and kits for in vivo imaging of cardiac sarcoidosis
CN113899909A (zh) * 2021-09-30 2022-01-07 上海交通大学医学院附属瑞金医院 可溶性cd206在制备抗中性粒细胞胞浆抗体相关性血管炎诊断试剂盒中的应用
US11833170B2 (en) 2022-02-04 2023-12-05 Navidea Biopharmaceuticals, Inc. Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
US20230302041A1 (en) * 2022-03-25 2023-09-28 Navidea Biopharmaceuticals, Inc. Competitive Self-Blocking with Unlabeled Manocept Imaging Agents
EP4525882A1 (en) 2022-05-20 2025-03-26 Navidea Biopharmaceuticals, Inc. Cd206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker
JP2025535006A (ja) 2022-10-03 2025-10-22 ナビディア、バイオファーマスーティカルズ、インコーポレイテッド 炭水化物ポリマーに結合されたアミン終端リーシュへの糖部分のアミド結合
WO2024178142A1 (en) * 2023-02-22 2024-08-29 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
CN119592679B (zh) * 2024-11-25 2025-06-24 中日友好医院(中日友好临床医学研究所) 一种用于评估皮肌炎/抗合成酶综合征相关间质性肺疾病严重程度及预后的新型标记物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002544243A (ja) * 1999-05-14 2002-12-24 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 薬剤および診断薬の送達のための高分子担体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004085929A (ja) * 2002-08-27 2004-03-18 Fuji Photo Optical Co Ltd 光学素子
US20090311182A1 (en) * 2004-03-31 2009-12-17 Dong Wang Macromolecular Delivery Systems for Non-Invasive Imaging, Evaluation and Treatment of Arthritis and Other Inflammatory Diseases
US20100196272A1 (en) 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
SG166016A1 (en) * 2009-04-16 2010-11-29 Fan Wang Yiang Financial education planner and method of using thereof
US9101674B2 (en) * 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US20130330274A1 (en) * 2012-05-22 2013-12-12 University of Virginia Patent Foundation d/b/a University of Virginia Licensing & Ventures Group Compositions and methods for detecting and treating cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002544243A (ja) * 1999-05-14 2002-12-24 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 薬剤および診断薬の送達のための高分子担体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A M Balazuc et al, Microbes and Infection (2005), vol 7, pp 969-975.
David R Vera et al, Nuclear Medicine and Biology (2005), vol 32, pp 687-693.
Paul C Brown et al, Tertiary Pharmacology Review (2011), Reference ID:315224, pp1-129.

Also Published As

Publication number Publication date
CN105764529A (zh) 2016-07-13
AU2022205225A1 (en) 2022-08-04
US20220016272A1 (en) 2022-01-20
JP2016527252A (ja) 2016-09-08
IL243645A0 (en) 2016-02-29
ZA201600453B (en) 2019-09-25
AU2020200293B2 (en) 2022-04-21
EP3024493A1 (en) 2016-06-01
KR20210095972A (ko) 2021-08-03
JP6607854B2 (ja) 2019-11-20
KR20160055791A (ko) 2016-05-18
CN114377143A (zh) 2022-04-22
CA2918782A1 (en) 2015-01-29
WO2015013341A1 (en) 2015-01-29
HK1225623A1 (zh) 2017-09-15
AU2014293198A1 (en) 2016-02-04
AU2020200293A1 (en) 2020-02-06
US20150023876A1 (en) 2015-01-22
CA2918782C (en) 2024-03-12
IL243645B (en) 2019-12-31

Similar Documents

Publication Publication Date Title
AU2020200293B2 (en) Compositions, methods and kits for diagnosing and treating CD206 expressing cell-related disorders
US12097264B2 (en) Methods and compositions for theranostic nanoparticles
EP3156078B1 (en) Fucoidans as ligands for the diagnosis of degenerative pathologies
Lesniak et al. Evaluation of PSMA-targeted PAMAM dendrimer nanoparticles in a murine model of prostate cancer
Kryza et al. Biodistribution study of nanometric hybrid gadolinium oxide particles as a multimodal SPECT/MR/optical imaging and theragnostic agent
Hong et al. Positron emission tomography imaging of CD105 expression during tumor angiogenesis
US11154625B2 (en) Fucoidans as ligands for the diagnosis of degenerative pathologies
Kang et al. 64Cu-Labeled tetraiodothyroacetic acid-conjugated liposomes for PET imaging of tumor angiogenesis
Chen et al. Multifunctional gold nanocomposites designed for targeted CT/MR/optical trimodal imaging of human non-small cell lung cancer cells
US20210338848A1 (en) Compositions and methods for diagnosing and treating macrophage-related disorders using carbohydrate-based macromolecular carrier
Prasanphanich et al. The effects of linking substituents on the in vivo behavior of site-directed, peptide-based, diagnostic radiopharmaceuticals
HK40073647A (en) Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders
US20220280659A1 (en) Targeted Nanoparticles of Well-Defined and Reproducible Sizes
Liu et al. PEGylated and non-PEGylated TCP-1 probes for imaging of colorectal cancer
Amato et al. Radioimmunodetection of residual, recurrent or metastatic germ cell tumors using technetium-99 anti-(α-fetoprotein) Fab′ fragment
Facca EGFR and HER2-targeted radioimmunoconjugates for theranostic molecular imaging and Auger electron radioimmunotherapy of breast cancer
CA3022354C (en) Methods and compositions for theranostic nanoparticles
Müller et al. Folate Receptor-Targeted Radionuclide Imaging Agents
Buckway Image-guided therapeutic delivery to solid tumors with HPMA copolymers

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240728

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240728

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000